Bioasis Technologies Inc. V.BTI

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

TSXV:BTI - Post by User

Bioasis Technologies Inc. > Prothena

<< Previous

Bullboard Posts

Next >>

Comment by barsaxon Feb 25, 2021 9:47am

122 Views

Post# 32656730

RE:Prothena

One of the payload modalities of the xB3 platform are antibodies. I have no idea if the Prothena antibody in this instance uses the xB3 platform to get across the BBB:

Title: Microtubule Binding Region (MTBR)-Specific Antibody PRX005 Prevents Pathological Tau Progression Via Blockade of Neuronal Internalization
Session: Tau Pathology and Therapeutic Strategies 1
Date and Time: Thursday, March 11, 13:30 - 13:45 CET
Presenter: Philip J. Dolan, PhD, Director, Protein Sciences, Prothena